Starr (1969) reported the first clinical work, performed in the period 1967–1969, on the simultaneous use of intravenous MLT at high doses in combination with adrenocorticotropic hormone (ACTH) in a group of patients affected with sarcomas of soft tissues [26]. The gene discussed is POMC; the disease is soft tissue sarcoma.